Atricure, INC Schedule 13G passive stakes

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 6.8% of AtriCure, Inc. common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.08% of AtriCure Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.51% of AtriCure Inc.'s common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in AtriCure Inc. following an internal organizational realignment.

Macquarie Group Limited and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 4.60% in AtriCure Inc's common shares.

BlackRock, Inc. has reported an increased beneficial ownership of 7.8% in AtriCure Inc.'s common stock, holding 3,862,837 shares as of September 30, 2025.

Macquarie Group Limited and its affiliates have reported a 5.06% beneficial ownership stake in AtriCure Inc., totaling 2,503,205 common shares.

Wellington Management Group LLP and its affiliates have reported an 8.0% beneficial ownership stake in AtriCure, Inc. common stock.

Champlain Investment Partners, LLC has filed a Schedule 13G, revealing a 4.4% beneficial ownership stake in medical device company AtriCure, Inc.

Hood River Capital Management LLC has filed an amended Schedule 13G, revealing a 6.00% passive beneficial ownership stake in AtriCure, Inc. as of December 31, 2024.